InnoCare Pharma is advancing the development of orelabrutinib, a novel therapeutic agent targeting primary immune thrombocytopenia (ITP), expanding treatment options for this autoimmune disorder.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.